Holen Sie sich die Stockscreener-App
8.365
3.35%
0.315
Schlusskurs vom Vortag:
$8.05
Offen:
$7.87
24-Stunden-Volumen:
17,012
Relative Volume:
0.45
Marktkapitalisierung:
$89.32M
Einnahmen:
$49.98M
Nettoeinkommen (Verlust:
$-9.64M
KGV:
-11.78
EPS:
-0.71
Netto-Cashflow:
$-4.86M
1W Leistung:
+32.70%
1M Leistung:
+31.02%
6M Leistung:
+20.41%
1J Leistung:
+69.45%
1-Tages-Spanne:
$7.87
$8.3423
1-Wochen-Bereich:
$6.30
$8.5799
52-Wochen-Spanne:
$3.6001
$11.99
Champions Oncology Inc Stock (CSBR) Company Profile
Firmenname
Champions Oncology Inc
Sektor
Branche
Telefon
410-369-0365
Adresse
855 N. WOLFE STREET, BALTIMORE, NJ
Vergleichen Sie CSBR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CSBR
Champions Oncology Inc
|
8.33 | 89.32M | 49.98M | -9.64M | -4.86M | -0.71 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.98 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
513.42 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.42 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
539.92 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
254.36 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Champions Oncology Inc Stock (CSBR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-09-12 | Hochstufung | Craig Hallum | Hold → Buy |
| 2019-11-18 | Eingeleitet | The Benchmark Company | Speculative Buy |
Champions Oncology Inc Aktie (CSBR) Neueste Nachrichten
Champions Oncology: Biological IP Is The Real AssetNot Preclinical Services - Seeking Alpha
Champions Oncology, Inc.'s (NASDAQ:CSBR) 11% gain last week benefited both private equity firms who own 30% as well as insiders - Yahoo Finance
After A Standout Q3, What's On The Horizon For Champions Oncology? - RTTNews
"STRONGER TOGETHER": SWITZERLAND CHAMPIONS INTERNATIONAL PARTNERSHIPS AS KEY TO ACCELERATED INNOVATION", ONCE AGAIN SWITZERLAND IS SHOWCASING ITS BIOTECH EXCELLENCE AT BIO INTERNATIONAL IN BOSTON 1 - Yahoo
How To Trade (CSBR) - news.stocktradersdaily.com
Humanized Mouse and Rat Model Market worth US$409.8 million - openPR.com
Humanized Mouse and Rat Model Market worth US$409.8 million in 2030 with 8.2% CAGR | MarketsandMarkets™ - Barchart.com
(CSBR) Long Term Investment Analysis - news.stocktradersdaily.com
Positive Sentiment Still Eludes Champions Oncology, Inc. (NASDAQ:CSBR) Following 26% Share Price Slump - simplywall.st
Sixth Annual Champions Gala Raises Money for Lehigh Valley Topper Cancer Institute - Lehigh Valley Health Network
Heartland Oncology and Hematology Oncologist Named 2025 Advocacy Champion by the Association for Clinical Oncology (ASCO) - Seeking Alpha
Leading Oncologist Wins ASCO's Top Advocacy Award for Fighting Cancer Care Barriers - Stock Titan
Champions Oncology Reports Quarterly Revenue of $14.1 Million Adjusted EBITDA of $2.0 Million - ACCESS Newswire
Where are the Opportunities in (CSBR) - news.stocktradersdaily.com
Champions Oncology Says It Has Obtained License to Use Radioactive Materials in Preclinical Studies - marketscreener.com
CSBR Secures License for Radioactive Material Use in Preclinical Studies | CSBR Stock News - GuruFocus
Champions Oncology Obtains Radioactive Materials License to Advance Comprehensive Radiotherapeutic Studies In-House - Bellingham Herald
Press Release Distribution & PR Platform - ACCESS Newswire
Champions Oncology Unlocks Next-Gen Cancer Treatment Capabilities with Strategic Radiotherapy License - Stock Titan
Champions Oncology Reports Record Quarterly Revenue of $9.5 Million - ACCESS Newswire
Champions Oncology Reports Quarterly Revenue of $12.9 Million - ACCESS Newswire
Champions Oncology Reports Quarterly Revenue of $12.0 Million - ACCESS Newswire
Champions Oncology (CSBR) Partners with Turbine to Boost Drug Di - GuruFocus
Champions Oncology's Data Platform Gains Momentum through a Strategic Collaboration with Turbine - Stock Titan
Turbine Launches the World’s First Virtual Lab Using Cell Simulations - Business Wire
Humanized Mouse and Rat Model Market worth US$409.8 million in 2030 with 8.2% CAGR | MarketsandMarkets - The Malaysian Reserve
Champions Oncology's (NASDAQ:CSBR) investors will be pleased with their respectable 47% return over the last year - Yahoo
I-Apollo Hospitals, yethula i-“Cancer Champions United” isinyathelo esiyingqayizivele sokunikeza amandla Abasinde Ngomdlavuza! - Apollo Hospitals
Patient Derived Xenograft Model Market Future Business - openPR.com
Champions Oncology Reports Record Quarterly Revenue of $7.7 Million For The Fourth Quarter Ended April 30, 2019 - ACCESS Newswire
Investors Give Champions Oncology, Inc. (NASDAQ:CSBR) Shares A 28% Hiding - simplywall.st
American Battery Technology boosts recycled battery output - Investing.com
Apollo Hospitals, yakhazikitsa "Cancer Champions United" njira yapadera yopatsa mphamvu Opulumuka Khansa! - Apollo Hospitals
Pre-market Movers: PTPI, ACON, HUMA, TNON... - RTTNews
CHAMPIONS ONCOLOGY, INC. SEC 10-Q Report - TradingView
Champions Oncology Third Quarter 2025 Earnings: EPS: US$0.33 (vs US$0.19 loss in 3Q 2024) - Yahoo Finance
Champions Oncology target raised to $12 at Craig-Hallum By Investing.com - Investing.com Canada
Champions Oncology, Inc. (NASDAQ:CSBR) Q3 2025 Earnings Call Transcript - MSN
Earnings call transcript: Champions Oncology Q1 2025 earnings beat expectations By Investing.com - Investing.com South Africa
Finanzdaten der Champions Oncology Inc-Aktie (CSBR)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.59%
0.56%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):